Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Translational and tailored, but can we afford it?

EACR 2012

7 - 10 Jul 2012

Published: 17 Jul 2012

Views: 4455

Rating:

Save

Prof Gordon McVie - European Institute of Oncology and ecancer

Prof McVie introduces the symposium, 'Translational and tailored, but can we afford it?', at the 22nd European Association for Cancer Research, Barcelona, 8th July 2012.

The official EACR-22 sponsored satellite symposium was hosted by ecancer, in partnership with EurocanPlatform and Vall d’Hebron Institute of Oncology.

Related Videos

Enhancing cancer care in Africa: Patient perspectives and quality improvement

Dr Verna Vanderpuye - Korle-Bu Teaching Hospital, Accra, Ghana

Enhancing cancer care in Africa: Patient perspectives and quality improvement ( Dr Verna Vanderpuye - Korle-Bu Teaching Hospital, Accra, Ghana )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru

The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Global adoption of single-shot targeted IORT for breast cancer

Dr Jayant Vaidya - University College London, London, UK

Global adoption of single-shot targeted IORT for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

More from ecancer